Author

I. Spasojevic

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Organism:C. elegans· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Briley· 1 shared A. Floyd Averette· 1 shared A. Mangoli· 1 shared A. Rivera· 1 shared B. T. Whitfield· 1 shared C. Fraley· 1 shared C. J. Pirozzi· 1 shared D. M. Ashley· 1 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Briley

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Enhanced fungal specificity and in vivo therapeutic efficacy of a C-22 modified FK520 analog against C. neoformans

A. Rivera, W. Lim, E. Park, P. A. Dome, M. J. Hoy, I. Spasojevic, S. Sun, A. Floyd Averette, S. Pina-Oviedo, P. R. Juvvadi, W. J. Steinbach, M. Ciofani, J. Hong, J. Heitman

This paper identifies a modified FK520 analog, JH-FK-08, with reduced immunosuppression and improved antifungal efficacy against C. neoformans in vivo.

bioRxiv · Jun 5, 2023Microbiology

Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas

S. Hariharan, B. T. Whitfield, C. J. Pirozzi, M. S. Waitkus, M. C. Brown, M. L. Bowie, D. M. Irvin, K. Roso, R. Fuller, J. Hostettler, S. Dharmaiah, E. A. Gibson, A. Briley, A. Mangoli, C. Fraley, , D. M. Ashley

This study shows that ATRX loss primes glioma cells for innate immune recognition, while IDH1R132H mutation suppresses immune signaling, which can be reversed by IDH1 inhibition.

bioRxiv · Apr 20, 2023 · PreprintCancer Biology

A testosterone metabolite 19-hydroxyandrostenedione induces neuroendocrine trans-differentiation of prostate cancer cells via an ectopic olfactory receptor

T. Abaffy, J. R. Bain, M. J. Muehlbauer, I. Spasojevic, S. Lodha, E. Bruguera, S. K. Neal, S. Y. Kim, H. Matsunami

This study identifies 19-hydroxyandrostenedione as an endogenous agonist of OR51E2 that induces neuroendocrine trans-differentiation in prostate cancer cells.

bioRxiv · Jan 4, 2018Cancer Biology